Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P48546
UPID:
GIPR_HUMAN
Alternative names:
Glucose-dependent insulinotropic polypeptide receptor
Alternative UPACC:
P48546; B7WP14; B7ZKQ0; Q14401; Q16400; Q52M04; Q9UPI1
Background:
The Gastric inhibitory polypeptide receptor, also known as the Glucose-dependent insulinotropic polypeptide receptor, plays a pivotal role in metabolic processes. Identified by its unique identifier P48546, this receptor is integral in mediating the effects of GIP through G proteins that activate adenylyl cyclase. Its involvement in the regulation of insulin secretion in response to glucose makes it a critical component in maintaining glucose homeostasis.
Therapeutic significance:
Understanding the role of the Gastric inhibitory polypeptide receptor could open doors to potential therapeutic strategies. Its central function in glucose metabolism and insulin regulation positions it as a promising target for the development of treatments for metabolic disorders.